drugset / Trial / NCT03908814
Phase I Clinical Trial of Human Anti-PD-L1 Antibody Injection (LDP) in Patients With Advanced Malignant Tumors
Phase 1
Completed
66 enrolled
Dragonboat Biopharmaceutical Company Limited
Shanghai East Hospital · collab
NaSequentialOpen-labelTreatment
Summary
This is a phase I, open-label, multiple-dose, dose-escalation study to evaluate the safety, tolerability, pharmacokinetics and anti-tumor activity of LDP in subjects with advanced malignant tumors.
Timeline
- Start
- 2019-04-27
- Primary completion
- 2023-04-10
- Completion
- 2023-04-10
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | LDP | Monoclonal antibody | 0.1 mg/kg | — |
| Subject | LDP | Monoclonal antibody | 0.3 mg/kg | — |
| Subject | LDP | Monoclonal antibody | 1 mg/kg | — |
| Subject | LDP | Monoclonal antibody | 3 mg/kg | — |
| Subject | LDP | Monoclonal antibody | 10 mg/kg | — |
| Subject | LDP | Monoclonal antibody | 20 mg/kg | — |
Indications
No indication recorded.